IMCR vs. TWST, DNLI, ACLX, IOVA, SWTX, VCEL, RXRX, APGE, KYMR, and ADMA
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Twist Bioscience (TWST), Denali Therapeutics (DNLI), Arcellx (ACLX), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.
Immunocore has higher revenue and earnings than Twist Bioscience. Immunocore is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
Twist Bioscience has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
In the previous week, Immunocore had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 20 mentions for Immunocore and 5 mentions for Twist Bioscience. Immunocore's average media sentiment score of 0.74 beat Twist Bioscience's score of 0.18 indicating that Twist Bioscience is being referred to more favorably in the media.
Immunocore has a net margin of -22.60% compared to Immunocore's net margin of -69.24%. Twist Bioscience's return on equity of -16.54% beat Immunocore's return on equity.
Twist Bioscience received 41 more outperform votes than Immunocore when rated by MarketBeat users. However, 70.59% of users gave Immunocore an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
Twist Bioscience currently has a consensus price target of $42.50, indicating a potential downside of 9.59%. Immunocore has a consensus price target of $81.85, indicating a potential upside of 53.59%. Given Twist Bioscience's higher probable upside, analysts plainly believe Immunocore is more favorable than Twist Bioscience.
84.5% of Immunocore shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by company insiders. Comparatively, 9.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Immunocore beats Twist Bioscience on 12 of the 18 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
